Latest:
The Potential of Oral HMAs in MDS
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Guiseppe Visani, MD
Latest:
Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AML
Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.
Gunter von Minckwitz, MD
Latest:
Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer
Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.
Gunter von Minckwitz, MD, PhD
Latest:
Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer
Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.
Gustavo Fernandez, MD
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Gustavo Olivera PhD
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation
Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Guy Young, MD
Latest:
Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer
Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.
Gyorgy Petrovics, PhD
Latest:
Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients
Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.
Habte A. Yimer, MD
Latest:
Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma
Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).
Hagop M. Kantarjian, MD
Latest:
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
Dr. Hagop Kantarjian presents the Phase I/II SAVE trial results, showcasing the promising efficacy and safety of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in relapsed/refractory AML, achieving high response rates and MRD negativity in heavily pretreated patients.